A groundbreaking AI initiative is reshaping rare disease management, promising timely diagnosis but raising questions about privacy and data security.
Story Highlights
- The AI platform initially targeting GPP is now expanding to include HS, broadening its impact on rare disease care.
- Backed by the AAD, OM1, and pharmaceutical giant Boehringer Ingelheim, the initiative aims to enhance patient outcomes.
- Data aggregation and AI are key to addressing the historically delayed diagnosis of rare conditions.
- The project underscores the growing role of AI in transforming healthcare, despite privacy concerns.
Expansion of AI-Driven Platform
The American Academy of Dermatology (AAD), in collaboration with OM1 and Boehringer Ingelheim, is enhancing its AI platform initially developed for generalized pustular psoriasis (GPP) to now include hidradenitis suppurativa (HS). This strategic expansion aims to improve the diagnosis and treatment of these rare, complex skin conditions by utilizing AI and vast patient data from the DataDerm registry.
The initiative leverages OM1’s PhenOM AI Patient Finder tool, which maps patient journeys and disease progression. By integrating this AI technology with a registry of 50 million deidentified patient encounters, the project seeks to reduce diagnosis delays and improve care. This expansion marks a significant advancement in dermatological patient management, addressing unmet needs in GPP and HS care.
The September issue of IJD has been released, featuring new indicators for hidradenitis suppurativa and updates in psoriasis epidemiology. I was pleased to contribute by editing several technology-focused articles, including those on AI. pic.twitter.com/L4FLzemMrH
— Mohamad Goldust, MD (@MohamadGoldust) September 5, 2025
Significance and Stakeholders
The significance of this project lies in its ability to transform care pathways for rare diseases, where delayed diagnosis and treatment have been persistent issues. The AAD, as the project sponsor, aims to advance dermatology practice and improve patient outcomes. OM1’s role is to demonstrate the value of AI in healthcare, while Boehringer Ingelheim supports innovation that aligns with its therapeutic interests. Patients and clinicians stand to benefit from improved identification tools and educational resources.
Collaboration among professional societies, tech companies, and pharmaceutical partners enhances the initiative’s reach and resource mobilization. The leadership of AAD, supported by key opinion leaders in dermatology, plays a pivotal role in guiding the project’s direction and impact.
Watch;
Impact and Challenges
Short-term, the initiative promises better patient identification and diagnosis, leading to more timely treatment. Long-term, it could reduce morbidity and mortality associated with GPP and HS, providing data-driven insights for future AI applications in dermatology. However, the expansion brings challenges, including ensuring patient privacy and data security. As AI tools become more integrated into healthcare, maintaining public trust and compliance with regulations will be crucial.
The broader implications for the industry include demonstrating the scalability of AI-powered patient identification across multiple diseases. This project sets a precedent for data-driven, collaborative approaches in specialty medicine, potentially influencing policy and reimbursement strategies for rare diseases.
Sources:
Generalized Pustular Psoriasis Education Initiative Will Improve Care for Patients
AI and Machine Learning in Dermatology
AI’s Role in Dermatological Diagnosis
AAD Generalized Pustular Psoriasis Education Initiative
